MSC-BlackRock Deal

Showing 952 articles
Business

C4 Therapeutics: Can Its Protein-Degrading Tech Ignite a Biotech Rally?

Amid a challenging market for biotech, C4 Therapeutics (NASDAQ: CCCC) is drawing investor attention with its targeted protein degradation platform. Backed by industry giants and focused on niche cancers, the clinical-stage company presents a high-risk, high-reward proposition. We examine the bull case and the road ahead.

Business

Starz Entertainment: The Bull Case for a Streaming Underdog

Following a sharp post-spinoff rally and subsequent pullback, Starz Entertainment (STRZ) is drawing value investors with its deep discount, niche content strategy, and a restructuring plan aimed at sustainable cash flow. Activist stakes and potential M&A add further intrigue to the story.

Business

REV Group Merges Into Terex, Shifting Investor Landscape and Strategic Focus

The completion of REV Group's merger with Terex Corporation marks a significant corporate realignment, moving the specialty vehicle manufacturer from a standalone NYSE listing to a subsidiary within a larger industrial equipment platform. This restructuring alters how investors track performance and assess exposure to key markets like emergency services and recreational vehicles.